Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: Implications for monitoring monoclonal gammopathies

Clinical Chemistry

Volumn 57, Issue 12, 2011, Pages 1687-1692

  Katzmann, Jerry A ^a   Snyder, Melissa R ^a   Rajkumar, S Vincent ^a   Kyle, Robert A ^a   Therneau, Terry M ^a   Benson, Joanne T ^a   Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL MONITORING; CLONAL VARIATION; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; MONOCLONAL IMMUNOGLOBULINEMIA; MONOCLONAL SERUM FREE LIGHT CHAIN IMMUNOASSAY; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; SPIKE; URINE PROTEIN ELECTROPHORESIS;

BLOOD PROTEIN ELECTROPHORESIS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULINS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEPHELOMETRY AND TURBIDIMETRY; PARAPROTEINEMIAS; TIME FACTORS;

EID: 82755190444     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.171314     Document Type: Article

References (18)

1. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73. (Pubitemid 44264086)
2. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410-51.
3. Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem 2009;55:1523-9.
4. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
5. Fraser CG. Biological variation: from principles to practice. Washington (DC): AACC Press, 2001.
6. Smellie WSA. What is a significant difference between sequential laboratory results? J Clin Pathol 2008;61:419-25. (Pubitemid 351518221)
7. Beal SL, Sheiner LB. Heteroscadastic nonlinear regression. Technometics 1988;30:327-37.
8. Ricós C, García-Lario J-V, Alvares V, Cava F, Domenech M, Hernández A, et al. Biological variation database, and quality specifications for imprecision, bias and total error (desirable and minimum): the 2010 update. http://www.westgard.com/biodatabase-2010-update.htm (Accessed September 2011).
9. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28. (Pubitemid 41098849)
10. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44. (Pubitemid 34925779)
11. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684-90.
12. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PM. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84. (Pubitemid 36819341)
13. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111:4908-15.
14. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378-83.
15. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005;36:597-600. (Pubitemid 43115014)
16. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/-thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Hematol 2007;139:224-33. (Pubitemid 47495869)
17. Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, et al. Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol 2011;29:674-81.
18. Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, et al. Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predict outcome following therapy in primary amyloidosis. Am J Hematol 2011;86:251-5.